Devyser Diagnostics AB (DVYSR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Devyser Diagnostics AB (DVYSR) has a cash flow conversion efficiency ratio of 0.034x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr12.10 Million ≈ $1.30 Million USD) by net assets (Skr357.90 Million ≈ $38.52 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Devyser Diagnostics AB - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Devyser Diagnostics AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read DVYSR liabilities breakdown for a breakdown of total debt and financial obligations.
Devyser Diagnostics AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Devyser Diagnostics AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eureka Group Holdings Ltd
AU:EGH
|
0.029x |
|
coocon Corp.
KQ:294570
|
0.050x |
|
Epsilon Energy Ltd
NASDAQ:EPSN
|
-0.004x |
|
Bergbahnen Engelberg Truebsee Titlis Bet AG
SW:TIBN
|
0.062x |
|
Asian Sea Corporation Public Company Limited
BK:ASIAN
|
0.060x |
|
Aemetis Inc
NASDAQ:AMTX
|
0.033x |
|
CVC Brasil Operadora e Agencia
SA:CVCB3
|
0.373x |
|
AMA Group Limited
F:KC7
|
0.047x |
Annual Cash Flow Conversion Efficiency for Devyser Diagnostics AB (2018–2025)
The table below shows the annual cash flow conversion efficiency of Devyser Diagnostics AB from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Devyser Diagnostics AB.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr354.30 Million ≈ $38.13 Million |
Skr8.20 Million ≈ $882.45K |
0.023x | +117.26% |
| 2024-12-31 | Skr349.00 Million ≈ $37.56 Million |
Skr-46.80 Million ≈ $-5.04 Million |
-0.134x | +25.91% |
| 2023-12-31 | Skr385.10 Million ≈ $41.44 Million |
Skr-69.70 Million ≈ $-7.50 Million |
-0.181x | -92.80% |
| 2022-12-31 | Skr431.44 Million ≈ $46.43 Million |
Skr-40.50 Million ≈ $-4.36 Million |
-0.094x | -137.32% |
| 2021-12-31 | Skr416.68 Million ≈ $44.84 Million |
Skr-16.48 Million ≈ $-1.77 Million |
-0.040x | -294.14% |
| 2020-12-31 | Skr30.77 Million ≈ $3.31 Million |
Skr627.00K ≈ $67.48K |
0.020x | -94.85% |
| 2019-12-31 | Skr37.01 Million ≈ $3.98 Million |
Skr14.63 Million ≈ $1.57 Million |
0.395x | +96.80% |
| 2018-12-31 | Skr29.97 Million ≈ $3.23 Million |
Skr6.02 Million ≈ $647.85K |
0.201x | -- |
About Devyser Diagnostics AB
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, … Read more